ST13, Hsp70 interacting protein pseudogene 20Genealiases: []
Q-omics provides the consensus-scored ST13P20 profile across patient tissues and cancer cell-line models. ST13P20 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ST13P20 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ST13P20 RNA expression shows 12,574 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRP, and GBM as cancer lineages where ST13P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST13P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST13P20 survival associations across molecular data types. ST13P20 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST13P20 RNA expression–survival associations across cancer types. High ST13P20 expression shows unfavorable associations in BLCA, DLBC, UCEC, CHOL and SKCM, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for ST13P20 RNA expression.
This table summarizes ST13P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ST13P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST13P20 shows lower tumor expression in KIRP, KIRC, LUAD, HNSC, THCA and KICH. The KIRP box plot shows higher ST13P20 RNA expression in normal versus tumor tissue (log2 FC = −0.217, t-test p < 0.001).
This table shows molecular features associated with ST13P20 in patient tissues and cancer cell lines. In patient samples, ST13P20 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
